Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide.
Inflammation is a prominent feature of several disorders characterized by primary demyelination, but it is not clear whether a relationship exists between inflammation and myelin damage. We have found that substantial demyelination results from the focal inflammatory lesion caused by the injection of lipopolysaccharide (LPS; 200 ng) directly into the rat dorsal funiculus. Within 24 h, such injections caused a focal inflammatory response consisting of a substantial number of polymorphonuclear cells and ED1-positive and inducible nitric oxide synthase (iNOS)-positive macrophages/microglia. The number of inflammatory cells was substantially reduced by day 7. OX-52-positive T-cells were less frequently observed but were present in the meninges at 8 h, reached a maximum in the dorsal funiculus at 7 days, and were rare at 14 days. The inflammation was followed by the appearance of a large lesion of primary demyelination that encompassed up to approximately 75% of the cross-sectional area of the dorsal funiculus. Treatment with dexamethasone significantly reduced the number of cells expressing iNOS, but did not prevent the demyelination. By 28 days the lesions were largely remyelinated, usually by Schwann cells. These changes were not observed in control, saline-injected animals. We conclude that the intraspinal injection of LPS results in inflammation and subsequently in prominent demyelination. The mechanisms underlying the demyelination are not clear, but it is notable that it typically begins with disruption of the adaxonal myelin. Indeed, there is an early loss of myelin-associated glycoprotein within the lesion, despite the persistence of proteolipid protein. This combination is a feature of the pattern III lesion recently described in multiple sclerosis (Lucchinetti et al., 2000), and we therefore suggest that LPS-induced demyelination may serve as the first experimental model available for the study of this type of multiple sclerosis lesion.
Felts
Paul A
PA
Department of Neuroimmunology and Neuroinflammation Research Group, Guy's, King's and St Thomas' School of Medicine, King's College London, London, UK. Paul.Felts@kcl.ac.uk
Woolston
Anne-Marie
AM
Fernando
Himali B
HB
Asquith
Stephen
S
Gregson
Norman A
NA
Mizzi
Oliver J
OJ
Smith
Kenneth J
KJ
D000818:Animals; D003711:Demyelinating Diseases / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D003907:Dexamethasone / Q000627:therapeutic use; D004926:Escherichia coli; D005727:Ganglia, Spinal / Q000276:immunology / Q000382:microbiology / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D007150:Immunohistochemistry / Q000379:methods; D007249:Inflammation; D007278:Injections, Spinal; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis; D007375:Interleukin-1 / Q000032:analysis; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008262:Macrophage Activation; D008297:Male; D017628:Microglia / Q000276:immunology; D023421:Models, Animal; D009103:Multiple Sclerosis; D020556:Neutrophil Infiltration; D019001:Nitric Oxide Synthase / Q000032:analysis; D052247:Nitric Oxide Synthase Type II; D051381:Rats; D017207:Rats, Sprague-Dawley; D012475:Salmonella; D012583:Schwann Cells / Q000473:pathology; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D013997:Time Factors
D005938:Glucocorticoids; D007375:Interleukin-1; D008070:Lipopolysaccharides; D018799:Intercellular Adhesion Molecule-1; D003907:Dexamethasone; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat